BioTelemetry (BEAT) Tops Q4 EPS by 4c

BioTelemetry (NASDAQ: BEAT) reported Q4 EPS of $0.15, $0.04 better than the analyst estimate of $0.11. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $45.89 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• GE Aerospace to acquire Consolidated Precision in $11.75b deal
• HSBC explains why risk assets continue to ignore every negative catalyst
• BMS myeloma CAR T therapy meets primary endpoint in phase 2 trial